Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 716 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $21,480.00. Following the sale, the chief operating officer now directly owns 343,311 shares in the company, valued at $10,299,330. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Enliven Therapeutics Trading Up 0.4 %
Shares of ELVN traded up $0.11 on Tuesday, reaching $28.98. 196,879 shares of the company's stock were exchanged, compared to its average volume of 260,880. The business has a 50 day moving average price of $24.38 and a two-hundred day moving average price of $22.84. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $30.03. The stock has a market capitalization of $1.36 billion, a P/E ratio of -15.02 and a beta of 1.10.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.17. Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.
View Our Latest Report on ELVN
Institutional Investors Weigh In On Enliven Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. Quest Partners LLC increased its stake in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after acquiring an additional 742 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Enliven Therapeutics during the first quarter worth $167,000. SG Americas Securities LLC bought a new position in shares of Enliven Therapeutics during the third quarter worth $256,000. The Manufacturers Life Insurance Company acquired a new position in shares of Enliven Therapeutics in the 2nd quarter valued at $322,000. Finally, Blackstone Inc. bought a new stake in shares of Enliven Therapeutics in the 1st quarter valued at $443,000. Institutional investors own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
